Pay in 4 interest-free payments of $6.83 Learn more
Ships within 48 hours · Estimated delivery Sep 6 - Sep 11
retatrutide trial sign up elilillyco is moving closer to bringing its next-generation obesity drug to regulators after reporting positive results from two additional Phase 3 trials. The experimental drug targets three hormone pathways, GIP, GLP-1 프로젠, 비만·당뇨 신약 'PG-102' Size:4 Pack primary_listing
프로젠, 비만·당뇨 신약 'PG-102' 개발 박차…전체 환자모집 완료 - 뉴스1
Each additional compound adds variables that make it harder to figure out what’s working and what’s hurting
primary_listing
Size:4 Pack
This hypothesis is supported by emerging data but has not been definitively confirmed in large trials
US$ 20.30
US$ 28.82
US$ 26.52
US$ 23.60
